Google
INTS — INTENSITY THERAPEUTICS, INC. COMMON STOCK (Healthcare >> Biotechnology)
INTS FAQ
What is INTS's ROE?
INTENSITY THERAPEUTICS, INC. COMMON STOCK reports a Return on Equity (ROE) of -107.16%.
What is INTS's dividend yield?
INTENSITY THERAPEUTICS, INC. COMMON STOCK offers a dividend yield of 0.00%.
What is INTS's Deepscope Quality Score?
Deepscope rates INTS's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy INTS?
Deepscope's AI Timing Score for INTS is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does INTS belong to?
INTENSITY THERAPEUTICS, INC. COMMON STOCK is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 3.67
Price
-0.07
(-1.87%)
Day Change
|
|
|---|
INTS, the overall quality is not good ( Quality = 46) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Current growth of ROA was below our criteria.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...
| Quality Factors |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 88 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 3.67 |
| PBV / Sector |
1.01 / 4.79
GREAT
|
| Earning Per Share | -3.88 |
| PE / Sector |
N/A / 18.05
|
| PEG or PE/Growth / Sector |
N/A / 0.62
|
| Average 1M Daily Value |
0.12 M
GREAT
|
| Average 1W Daily Value |
0.09 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
68% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-12 09:43:54 |
| Symbol | INTS |
| Name | INTENSITY THERAPEUTICS, INC. COMMON STOCK |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 2.70 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 10.11 / 9,010.81 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1 Enterprise Drive, Shelton, CT, United States, 06484-4779
Phone: 203 221 7381
Website: https://intensitytherapeutics.com
Sector: Healthcare >> Biotechnology
Description: Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
